PolarityTE Inc

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RegenETP, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm's products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. It was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareholder value by pursuing pre-market approval for SkinTE® from the U.S. Food and Drug Administration (FDA) through submission of an investigational new drug application (IND) and eventual biologics license application (BLA), and protecting our intellectual property. R

PolarityTE Provides Corporate Update

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/165,169 filed on October 19, 2018. This is the Company's second patent allowance in the United States. The newly allowed claims provide additional protection for methods of making skin-regenerative compositions with the Company's minimally polarized functional unit (MPFU) technology as well as methods of tr

PolarityTE Receives Allowance for Additional U.S. Patent

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the agreement by an accredited investor to exercise certain warrants to purchase up to an aggregate of 10,688,043 shares of common stock having an exercise price of $0.624 issued by the company in December 2020. The shares of common stock issuable upon exercise

PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrollment of 100 subjects in a randomized controlled trial (RCT) evaluating SkinTE® plus standard of care (SOC) versus SOC alone for the treatment of diabetic foot ulcers (DFUs). PolarityTE plans to report topline data via press release and presentation at the Symposium on Advanced Wound Care (SAWC) Spring 202

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today the closing of its previously announced registered direct offering. In the offering the company sold 6,670,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), pre-funded warrants to purchase up to 2,420,910 shares of C

PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor providing for the purchase and sale of 9,090,910 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a

PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

Do Options Traders Know Something About PolarityTE (PTE) Stock We Don't?

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value. The committee will focus on reviewing operational strategies and practices that advance the regulatory process for SkinTE and future financings, if any, that may be helpful in advancing the Company's strategies and making re

PolarityTE Announces Formation of Strategic Review Committee

PolarityTE (PTE) stock is soaring higher on Friday as investors prepare for its participation in an upcoming event on Monday. The post PTE Stock Alert: 7 Things for Investors to Know About PolarityTE as Shares Soar appeared first on InvestorPlace.

PTE Stock Alert: 7 Things for Investors to Know About PolarityTE as Shares Soar

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Virtual Bioconnect Conference on January 11, 2021. A webcast of the presentation will be available on January 11, 2021 beginning at 6:00 a.m. Eastern Time and can be accessed in the "News & Media/Events" section of PolarityTE's website at www.polarityte.com/news-media/events or via the f

PolarityTE to Present at the H.C. Wainwright Virtual Bioconnect 2021 Conference

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor providing for the purchase and sale of 10,688,043 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and

PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. This is the Company's first patent allowance in the United States. This patent application, which was originally filed on November 30, 2015, covers methods of making compositions for regenerating functional skin tissue using the Company's minimally polarized functional unit (MPFU) technology. The Company c

PolarityTE Receives Allowance for First U.S. Patent

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the dismissal with prejudice of a consolidated class action lawsuit filed in the United States District Court for the District of Utah under the caption In re PolarityTE, Inc. Securities Litigation, Case No. 2:18-cv-00510. The Court's order was based on the Comp

PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice

PolarityTE, Inc. (PTE) CEO David Seaburg On Q3 2020 Results - Earnings Call Transcript

PolarityTE, Inc.'s (PTE) CEO David Seaburg on Q3 2020 Results - Earnings Call Transcript

  Shares of PolarityTE (NASDAQ:PTE) moved higher by 7.3% in pre-market trading after the company reported Q3 results.

Recap: PolarityTE Q3 Earnings

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE will host a conference call and webcast today, November 9, 2020 at 8:00 a.m. ET. Highlights Total revenues were $3.34 million in Q3:20 compared to $1.40 million in Q3:19 SkinTE revenues were $1.16 million in Q3:20 compared to $0.84 million in Q3:19 Contract services r

PolarityTE Reports Third Quarter 2020 Results

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submitted in August 2020 regarding an indication for SkinTE to treat diabetic foot ulcers (DFUs). FDA's responses included, among other things, feedback and recommendations on SkinTE manufacturing, preclinical studies, clinical data submitted in the Company's briefing package, and additional clinical studies to

PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on November 9, 2020 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-599-8688 (U.S. and Canada) or +44 (0)330 336 9104 (International) with confirmation code

PolarityTE to Report Third Quarter 2020 Financial Results on November 9, 2020

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives. The termination of the shareholder rights plan, often referred to as a “poison pill,” is effective September 28, 2020. Shareholders are not required, nor do they need, to take any action because of the termination of this shareholder ri

PolarityTE Announces Termination of Shareholder Rights Plan

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an application titled, “Fluid Management System for Point of Care Device for Novel Regenerative Treatment for Chronic Wounds.” The Phase I grant, which totals approximately $245,000, is funded over a six-month period and will support research to apply for a subsequent larg

PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (RCT) evaluating SkinTE for the treatment of diabetic foot ulcers (DFUs), which previously reported statistically significant wound closure rates of 72% for SkinTE plus the standard of care (SOC) vs 32% for the SOC alone (p=0.005).

SkinTE™ Health Economics—DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M.

PolarityTE Expects Third Quarter Revenue to Meet or Exceed High-End of Guidance

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C.

PolarityTE to Present at H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Virtual Global Healthcare Conference

PolarityTE, Inc. (PTE) CEO David Seaburg on Q2 2020 Results - Earnings Call Transcript

News for PolarityTE Inc Stock (PTE)